GI
CYTK icon

GAMMA Investing’s Cytokinetics CYTK Stock Holding History

GAMMA Investing’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
2,487
+266
+12% +$19.1K 0.01% 1231
2026
Q1 		$146K Buy
2,221
+165
+8% +$10.5K 0.01% 1354
2025
Q4 		$131K Buy
2,056
+584
+40% +$36.3K 0.01% 1376
2025
Q3 		$80.9K Buy
1,472
+769
+109% +$31.7K ﹤0.01% 1660
2025
Q2 		$23.2K Sell
703
-417
-37% -$14.5K ﹤0.01% 2379
2025
Q1 		$45K Buy
1,120
+826
+281% +$38K ﹤0.01% 1864
2024
Q4 		$13.8K Sell
294
-305
-51% -$15.8K ﹤0.01% 2454
2024
Q3 		$31.6K Buy
599
+141
+31% +$7.86K ﹤0.01% 1814
2024
Q2 		$24.8K Sell
458
-158
-26% -$9.54K ﹤0.01% 1703
2024
Q1 		$43.2K Sell
616
-402
-39% -$31.1K 0.01% 1133
2023
Q4 		$79.5K Buy
+1,018
New +$36.9K 0.02% 643

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GAMMA Investing's CYTK Position: Q2 2026 in Review

GAMMA Investing increased its Cytokinetics (CYTK) stake by 12% in Q2 2026, buying an estimated $19.1K and bringing the position to 2,487 shares worth $212K. The position accounts for 0.01% of the portfolio, ranked #1231.

GAMMA Investing first reported a position in CYTK in Q4 2023 and has held it in 11 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • GAMMA Investing held 2,487 shares of Cytokinetics worth $212K as of Q2 2026.
  • GAMMA Investing bought 266 Cytokinetics shares in Q2 2026, an estimated $19.1K.
  • Cytokinetics made up 0.01% of GAMMA Investing's portfolio in Q2 2026, its #1231 holding.
  • GAMMA Investing first reported a position in Cytokinetics in Q4 2023 and has held it in 11 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.